Yüklüyor......
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
Drug tolerance is the basis for acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) including osimertinib, through mechanisms that still remain unclear. Here, we show that while AXL-low expressing EGFR mutated lung cancer (EGFRmut-LC) cells are more sensiti...
Kaydedildi:
| Yayımlandı: | Nat Commun |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Nature Publishing Group UK
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7490421/ https://ncbi.nlm.nih.gov/pubmed/32929081 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-020-18442-4 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|